India proposes rule to instantly suspend drug manufacturing licenses that fail government quality tests

India’s regulators have drafted new rules that would require an immediate suspension of any drug manufacturing license if the product does not meet quality standards in government testing. The proposal is aimed at tightening oversight and ensuring that substandard medicines are removed from the market without delay.

If adopted, the rule could force manufacturers to improve quality control processes and could lead to temporary shutdowns of facilities that fail inspections. Companies may need to invest in additional testing and compliance measures to avoid disruptions to their production lines.

At the same time, the article notes a slowdown in investigator‑initiated clinical trials in China after earlier regulatory relaxations had accelerated trial start‑ups. The tighter environment in both India and China reflects a broader shift toward stricter oversight of drug development and manufacturing.